-
Information-Publications
-
Engineered Extracellular Vesicle‐Delivered CRISPR/CasRx as a Novel RNA Editing ToolDetails
-
Tight Junction Component Occludin Binds to FIP5 to Regulate Endosome Trafficking and Mitotic Spindle FunctionDetails
-
AutoDock and molecular dynamics-based therapeutic potential prediction of flavonoids for primary Sjögren's syndromeDetails
-
Targeting Tumor Heterogeneity by Breaking a Stem Cell and Epithelial Niche Interaction LoopDetails
-
PHLDA1 suppresses TLR4-triggered proinflammatory cytokine production by interaction with tollipDetails
-
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injuryDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands